Propionic acidemia (Pa) and methylmalonic acidemia (MMa) comprise the most common organic acidemias and account for profound morbidity in affected individuals. although liver transplantation (lt) has emerged as a bulk enzyme-replacement strategy to stabilize metabolically fragile patients, it is not a metabolic cure because patients remain at risk for disease-related complications. We retrospectively studied lt and/or liver-kidney transplant in 9 patients with Pa or MMa with additional focus on the optimization of metabolic control and management in the perioperative period. Metabolic crises were common before transplant. By implementing a strategy of carbohydrate minimization with gradual but early lipid and protein introduction, lactate levels significantly improved over the perioperative period (P < 0.001). Posttransplant metabolic improvement is demonstrated by improvements in serum glycine levels (for Pa; P < 0.001 × 10 -14 ), methylmalonic acid levels (for MMa; P < 0.001), and ammonia levels (for Pa and MMa; P < 0.001). Dietary restriction remained after transplant. However, no further metabolic crises have occurred. Other disease-specific comorbidities such as renal dysfunction and cardiomyopathy stabilized and improved. in conclusion, transplant can provide a strategy for altering the natural history of Pa and MMa providing stability to a rare but metabolically brittle population. nutritional management is critical to optimize patient outcomes.
Original article | 1261 mutase (MUT), prior to entering the citric acid cycle for energy production. (2) PA is inherited in an autosomal-recessive fashion from mutations in either the PCCA or PCCB genes encoding the alpha and beta subunits, respectively, of PCC. MMA is caused by complete or partial deficiency of MUT (mut 0 enzymatic subtype or mut -enzymatic subtype, respectively), a defect in the transport or synthesis of its cofactor, adenosyl-cobalamin (cblA, cblB, or cblD-MMA), or deficiency of the enzyme methylmalonyl-CoA epimerase. (3) The clinical presentation of these disorders is that of "intoxication-type" neurological distress, a consequence of accumulating toxic compounds that are produced secondary to the metabolic block. (4) Generally, following an initial symptom-free period ranging from hours to days after birth, affected neonates with severe disease present with a spectrum of symptoms including food refusal, vomiting, progressive weight loss, generalized hypotonia, and abnormal posturing and movements. Progression to lethargy, seizures, and coma can occur, resulting in severe brain damage and death within a few days if not promptly treated. (5, 6) Biochemical and laboratory investigations reveal a combination of increased anion gap metabolic acidosis, leukopenia, thrombocytopenia, elevated lactate, anemia, ketonuria, and hyperammonemia. (5, 7) Diagnosis is made by elevated C3 carnitine levels in combination with specific urine and blood metabolites and is confirmed by enzymatic or molecular studies. (8) Treatment strategies are reflective of the clinical state, aimed at addressing the disease-specific complications of the initial acute presentation, longterm management, and intermittent metabolic decompensations that can occur from various triggers. Recent comprehensive reviews have been published, (2) and proposed guidelines are available. (8) Ultimately, these management strategies have improved survival but have not modified the poor neurodevelopmental prognoses for children affected by these disorders. (9) Other longterm complications include selective organ impairment from renal failure (MMA > PA), pancreatitis (PA > MMA), cardiomyopathy (CM; PA > MMA), and brain basal ganglia infarctions (MMA > PA). (8) The intensity of the medical management combined with frequent hospitalizations significantly impacts the quality of life of affected children and their families.
Bulk enzyme supplementation with liver transplantation (LT) as a therapeutic strategy for PA and MMA was first proposed in the early 1990s. (10) Given that the enzymes responsible for PA and MMA are expressed in all tissues of the body, it was not expected that LT would provide a metabolic cure; rather, LT was proposed as a way to stabilize metabolically fragile patients, minimize the risk of further decompensations, and improve quality of life. (11) More recent modifications to the organ allocation policies in the United States have given priority status to these disorders based on the risk of sudden life-threatening decompensation. The result has been the ability to list children with these disorders for transplant based solely on their diagnosis rather than disease-specific complications or severity. (12) Subsequent publications have reported on the experience of LT in the management of PA (11, (13) (14) (15) and MMA, (6, 16) and the application of statistical modeling has shown that LT may provide a societal benefit over traditional medical management by increasing both life years lived and quality of life years, while decreasing cost over a patient's lifetime. (17) However, robust data on transplant experiences with these rare diseases remain sparse. Thus, we report our center's experience with transplant in the management of PA and MMA, with an additional focus on the optimization of metabolic control and management in the perioperative period.
Patients and Methods
Children with a diagnosis of PA or MMA who underwent either a LT or liver-kidney transplantation (LKT) at the Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center were identified from the patient database. Their demographic, clinical, and laboratory data, including medical treatment prior to transplantation, indications for transplantation, pre-LT assessment, early management in intensive care unit, as well as longterm follow-up were analyzed. (18) using the creatinine-based Schwartz equation (19) before LT, or measured via radionuclide or serum cystatin C levels (normal < 1.1 mg/dL). For analysis of perioperative metabolic control, glycine was chosen as a PA-specific marker, whereas serum methylmalonic acid was used to reflect MMA patients. For analysis of posttransplant serum lactate levels, "early" measurements were defined as lactate levels obtained within the first week following transplant; "late" levels were defined as those obtained at normalization, discharge, or 4 weeks following transplant, whichever occurred first. At least 3 recordings were included in each group for each patient. Continuous data that were normally distributed are presented as the mean ± standard deviation (SD) and were analyzed by the 2-tailed Student t test. Differences were considered statistically significant if the P value was <0.05.
All information was gathered on a standardized form. Data were deidentified and coded by study number in accordance with the Health Insurance Portability and Accountability Act guidelines. The study was approved by the institutional review board at the University of Pittsburgh.
results

PatiEnt CHaRaCtERiStiCS
Nine transplants were performed for the indication of either PA (n = 3) or MMA (n = 6) between 2006 and 2017 with 100% patient and graft survival. The mean follow-up period was 3.5 years (range, 1-11.6 years). Five were female. Of the 9 patients, 5 had a genetically confirmed diagnosis. In the 3 MMA patients without documented genetic mutations, the patients were characterized as MUT0 based on enzymology. In the PA patient without a genetic confirmation (patient 3), the diagnosis was based on clinical presentation, biochemical abnormalities, and a history of a sibling with a genetic diagnosis with common parents. A total of 5 patients were born in the United States; 2 patients were referred from Saudi Arabia; and 2 were from Qatar. Four (patients 1, 4, 6, and 8) were diagnosed via expanded newborn screening. Within the analyzed cohort, there was 1 sibling relationship (patients 2 and 3). Consanguinity was present in all 3 patients with PA (Table 1) .
PREtRanSPlant
CHaRaCtERiStiCS anD CliniCal CoURSE
Of the 9 children, 8 (88.9%) of them initially presented within the first week of life, the exception being patient 7 who presented at 248 days of life with projectile vomiting, poor feeding, failure to thrive, and developmental delay ( Table 1) . Metabolic crises were common in most patients, often requiring hospitalization with supportive care despite optimal medical management. All patients were treated with protein restriction and carnitine supplementation. Medications to reduce blood ammonia levels included N-carbamylglutamate (n = 3) and sodium benzoate (n = 1). Metronidazole was frequently used, as was sodium citrate and trisodium citrate. The median protein restriction at the time of referral for transplant was 1.6 g/kg/day (range, 0.98-2.6 g/kg/day), and 8/9 required supportive feeding via a surgically placed gastrostomy tube.
Baseline liver, metabolic, and renal function studies are presented (Table 1) . Of the 6 patients with MMA, 5 were noted to have evidence of kidney impairment. Mild (patients 6 and 8), mild-to-moderate (patient 4), and moderate-to-severe (patients 5 and 7) injury was present in the cohort. Consistent with the disease processes, liver-specific biochemistries were relatively normal with only mild aminotransferase elevations noted in a minority of patients (patients 3, 5, 6, and 8). Synthetic function (total bilirubin and international normalized ratio [INR]) was normal for all patients. Serum glycine (mean, 1023.9 µmol/L; SD, 343.4) and methylmalonic acid (mean, 745 µmol/L; SD, 704.3) were elevated in PA and MMA patients, respectively. Hyperammonemia was common (mean, 57.4 µmol/L; SD, 29.1). Neurological and developmental deficits were frequently present in the cohort (Table 2) . Additional disease-related complications included dilated CM requiring pressor support (patient 1), metabolic stroke (patient 6), pancreatitis (patients 2 and 8), and pancytopenia (patient 6).
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PERioPERatiVE
CHaRaCtERiStiCS anD CliniCal CoURSE
Perioperative characteristics and related complications are noted (Table 3) . At the time of transplantation, the median age was 9.3 years (range, 1.2-21.6 years). LKT was performed in 5 of 6 patients with MMA, whereas all PA patients received LT alone. Whole liver grafts were used in 6 of 9 patients (5 were associated with LKT). Living donation was used in 2 patients (patients 1 and 2). Comprehensive anesthetic management, although an important consideration in this population, was unable to be thoroughly collected from the medical record. However, no patients were reported to require perioperative continuous hemodiafiltration. The median length of stay in the intensive care unit was 29.7 days, while the entire transplant-related hospitalization averaged 55 days.
Vascular Complications
Hepatic artery thrombosis (HAT) occurred in 2 patients. Intraoperatively, patient 9 developed a hepatic artery thrombus, necessitating Fogarty catheter thrombectomy followed by tissue plasminogen activator chemical thrombolysis with successful revascularization. Lovenox therapy was implemented for 9 months prior to switching to aspirin. Patient 1 developed a recurrent left HAT that did not resolve despite placement of an aortic conduit graft, resulting in an associated hepatic allograft infarction. Patient 5 developed a near-complete stenosis of the right hepatic vein at its junction with the inferior vena cava (IVC), which was managed with hepatic venoplasty and anticoagulation.
Metabolic Control
Serum lactate levels, as a reflection of metabolic control, significantly improved during the first posttransplant month (Fig. 1) . Early serum lactate levels, collected over the first week following transplant, were universally elevated (mean level, 5.2 µmol/L; range, 2.3-10.6 µmol/L). Late lactate levels (defined as those obtained at normalization, discharge, or 4 weeks following transplant, whichever occurred first) were significantly improved compared with the earlier levels (mean level, 2.9 µmol/L; range, 1-6.8 µmol/L). These findings were present in both the PA and MMA cohorts (Fig. 1) .
lonGtERM CHaRaCtERiStiCS anD CliniCal CoURSE
Transplant-and metabolic-related outcomes over a mean follow-up period of 3.5 years (range, 1-11.6 years) are presented (Tables 3 and 4 ). Patient and graft survival were 100%.
t Cell-Mediated Cellular Rejection
T cell-mediated rejection of the hepatic allograft was common with 15 episodes (14 histologically confirmed) occurring in 6 of 9 patients within the cohort. Patient 7 was noted to have 1 episode of renal rejection. Rejection episodes were primarily treated with steroids and increased immunosuppression (with or without adding additional immunosuppressive agents). Only patient 7 required antilymphocyte therapy for a steroid-unresponsive rejection episode that occurred 4 months after transplant.
Biliary Complications
Biliary complications were noted in both patients with HAT (patients 1 and 9). Additional biliary anastomotic strictures (patient 2 with biliary-enteric stricture and patient 4 with biliary anastomotic stricture) were noted. Percutaneous transhepatic biliary drainage catheter placement and serial balloon dilatations have been required for all patients. At last follow-up, only patient 4 remained with an in-dwelling biliary catheter due to recurrent anastomotic and central bile duct stricturing. 
Viremia
nutrition-and Metabolic-Related outcomes
All patients with PA remain on amino acid-modified supplementation (Propimex-2, Abbott, Chicago, IL; Table 4 ). Of the 6 MMA patients, all persisted Original article | 1267
with protein diet restriction but had stable methylmalonic acid and ammonia levels, 2 remained on a metabolic formula with a natural protein restriction to 1 g/kg/day, 1 patient had a protein intake of 1.35 g/kg/day protein, and 1 patient was on a low-protein diet at the time of their last follow-up visit. All patients continued to receive carnitine supplementation, and no patient suffered further metabolic crises in the posttransplant period. Posttransplant metabolic improvement is further demonstrated by improvements in serum glycine levels (for PA), methylmalonic acid levels (for MMA), and ammonia levels (PA and MMA). Mean serum glycine (1023.9 versus 259.1 µmol/L; P < 0.001 × 10 -14 ), methylmalonic acid (745 versus 154.9 µmol/L; P < 0.001), and ammonia levels (57.5 versus 40.9 µmol/L; P < 0.001) were significantly lower in the posttransplant period (Figs. 2 and  3 cardiac dilatation and left ventricular function noted on cardiac assessment 2 years following his transplant.
Discussion
PA and MMA cause life-threatening metabolic decompensation episodes and can result in serious sequelae. Although early detection with expanded newborn screening protocols and improvements in conventional substrate reduction therapy have led to an overall decrease in mortality, growth retardation and failure, poor nutritional status, selective organ impairment, and accumulative neurologic injury are persistent disease complications. (2, 6, 8, (20) (21) (22) (23) (24) LT (for PA and MMA) or LKT (for MMA) has shown efficacy in reducing and/or eliminating the risk of metabolic decompensation and markedly improves the quality of life of patients. (6, 8, 11, 14, 20) As such, transplant is now a commonly accepted therapeutic option for individuals with these devastating conditions. (25) Still, hesitancy remains largely due to incomplete metabolic control and the persistent (albeit reduced) risk of organ damage. (26) Our experience with transplant in PA and MMA highlights early difficulties in perioperative and postoperative metabolic management, but ultimately complete resolution of episodes of metabolic decompensation. We further seek to recommend considerations for early postoperative metabolic management based on our experience.
In our series, we show a 100% patient and graft survival in a cohort of 9 individuals transplanted with an underlying diagnosis of PA (n = 3) or MMA (n = 6) with a mean follow-up period of 3.5 years. For MMA, this is similar to other recent reports. (6, 27) Although our cohort is small, our experience with 0 mortality with PA and LT stands in contrast to reports of high mortality rates following transplant. (13, 28) Still, perioperative complications were common, underscoring the complexity of these diseases. Multiple confounders have been suggested to influence clinical outcomes after transplant including age, center experience, and comorbid conditions associated with the underlying disease. (6, 13) Of the 9 patients in our series, 4 (44%) were noted to have a significant perioperative complication, with the majority being vascular in nature (2 HAT and 1 hepatic vein/IVC stenosis). An additional 2 patients had biliary strictures that required intervention during the follow-up period. Although no HAT was noted in these patients during the perioperative period, compromised blood flow is a known risk for late biliary complications. (29) As such, future efforts to better understand Original article | 1269 the relationship between these OA and transplant-related vascular and biliary complications are needed.
Surgical considerations in this complex patient population include optimal graft selection to enhance chances of immediate wound closure and early extubation. More aggressive HAT prophylaxis is our practice based on earlier published experience demonstrating increased risk of thrombotic complications.
A primary indication for transplant in these disorders is to stabilize the medically fragile patient. Following transplant, markers of metabolic control in our patients were improved in both the perioperative and postoperative periods. The importance of appropriate metabolic support in the setting of PA and MMA is well recognized, (2, 8, 11) and recent reports have highlighted the preoperative and anesthetic considerations that complicate the transplant operation. (30) (31) (32) (33) As with the management of the disease prior to transplant, it is imperative that the immediate postoperative treatment minimizes catabolism to avoid metabolic decompensation. Clearly, the addition of partial enzyme replacement via a LT enables a "resetting" of the patient's metabolic fitness. Close monitoring is critical as fluids and nutritional support are introduced and adjusted in the early postoperative period. Lactate has been shown to be the most reliable parameter reflecting appropriate metabolic control. (8, 34) Our center's approach to the nutritional support of patients following transplant has been to gradually ease protein restriction toward the establishment of a new patient-specific baseline in the long term. In the early postoperative period promoting anabolism is problematic in the setting of early liver dysfunction and lactic acidosis, often associated with the transplant process itself combined with the frequent use of corticosteroids. There is intolerance of high-dose carbohydrate, and the use of insulin tends to exacerbate lactic acidosis. Our practice has been to aim for carbohydrate infusion rates of approximately 8 mg/kg/minute, in combination with the introduction of protein (0.5 g/kg/day) and lipid (1 g/kg/day) from day 1. We aim to meet full lipid (2 g/kg/ day) and protein intake (2 g/kg/day) on day 4 depending on the overall clinical and metabolic picture. This general approach has been successful given that serum lactate levels significantly improve over time after transplant. For the long term, we show improvements in serum glycine (for PA), methylmalonic acid (for MMA), and ammonia (for PA and MMA) following transplant, even with increased protein intake, which is consistent with other reports. Importantly, caution must be taken in attempting to over protocolize posttransplant support.
Multiple patient-and graft-related factors, including surgical and hospital-related stressors, contribute to the need to individualize and adjust medical and nutritional support. Finally, our experience adds to the emerging understanding that metabolic crisis recurrence can be all but eliminated following transplant.
Our study was limited by its size and retrospective nature. Most of the patients did not receive their pretransplant metabolic care at our institution, restricting the amount of clinical data that were available for review. Furthermore, although lactate has been shown to be a good indicator reflective of metabolic control, lack of routine testing once patients were in the outpatient setting limited its use for a more longterm analysis. Additionally, many of the confounders that can affect laboratory values, such as tourniquet application, use of central venous catheters versus peripheral access, temperature perturbations of the sample, and processing delays are unknown and unavailable for assessment. Furthermore, although glycine was used as a marker of disease control, medications such as sodium benzoate may have affected these levels by lowering what was recorded in the medical chart. As such, the preciseness of the data may be affected. Pretransplant developmental testing was not uniform, and posttransplant testing was not performed routinely. Finally, the medical record did not enable a thorough collection of nutritional support over the early posttransplant course. Percentages of enteral feeds, TPN, intravenous fluids, and per os intake were unable to be accurately quantified on any given day and what was ordered in the chart was not always reflected accurately in the medical record. Future efforts would benefit from a more acute focus on the perioperative nutritional management, likely in a prospective study.
In conclusion, we report a 100% survival in 9 patients and 14 transplanted organs (4 LTs and 5 LKTs) in a cohort of patients with PA and MMA. Perioperative and longterm complications are common, highlighting the medical complexity of these diseases. Wellrecognized disease-specific complications such as kidney disease (MMA) and CM (PA) improved and stabilized, and no patient developed disease-related metabolic crises following transplant. Although longterm dietary restriction cannot truly be normalized in these patients, we demonstrated that with close monitoring by an experienced multidisciplinary team, relaxed dietary protein restriction can safely occur early following transplant. Additional follow-up is required to determine if continued liberalization of dietary constraints is attainable in the long term. However, it is important to recognize that transplant does not fully correct the metabolic perturbations and that patients still have massive elevations of the OAs in the blood and organs after transplant. Therefore, although dietary protein tolerance is improved, the monitoring of and restriction to the recommended dietary allowance of total protein intake should be practiced.
